Showing 5151-5160 of 8223 results for "".
- Derms Urged to Step Up Role in Antibiotic Stewardshiphttps://practicaldermatology.com/news/derms-urged-to-step-up-role-in-antibiotic-stewardship/2458126/Dermatologists can and should play a larger role in antibiotic stewardship, according to researchers out of Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Data from the CDC shows the average dermatology provider wrote 669 antibiotic prescriptions in 2014, t
- Study: Soolantra is Both Anti-Inflammatory and Anti-Demodexhttps://practicaldermatology.com/news/study-soolantra-is-both-anti-inflammatory-and-anti-demodex/2458132/A recently published study sought to find scientific rationale for the dual anti-inflammatory and anti-parasitic mode of action of topical ivermectin 1% cream (Soolantra) in patients with rosacea. In a monocentric pilot study, 20 Caucasian patients with moderate to severe rosacea, as asse
- FDA Approves SciBase's Nevisense for Melanoma Detectionhttps://practicaldermatology.com/news/fda-approved-scibases-nevisense-for-melanoma-diagnosis/2458136/The FDA has approved the Scibase Pre-Market Approval (PMA) for Nevisense, a device for the early detection of malignant melanoma. According to the letter from the FDA the device is intended for use on cutaneous lesions with one or more clinical or historical characteristics of melano
- Foamix Pharmaceuticals Appoints David Domzalski as CEOhttps://practicaldermatology.com/news/foamix-pharmaceuticals-appoints-david-domzalski-as-ceo/2458137/Foamix Pharmaceuticals Ltd.'s Board of Directors has named David Domzalski Chief Executive Officer of the company effective immediately. Mr. Domzalski currently serves as President of Foamix's US subsidiary. He succeeds Dr. Dov
- No Need to Delay Certain Skin Procedures for Isotretinoin Patientshttps://practicaldermatology.com/news/no-need-to-delay-certain-skin-procedures-for-isotretinoin-patients/2458140/New consensus recommendations set the record straight on the timing of skin procedures for patients taking isotretinoin. After reviewing 32 relevant publications, the authors found “insufficient evidence” to support delaying manual dermabrasion, superficial chemical peels
- Survey: Despite Knowledge, Parents Don't Drive Kids' Sunscreen Usehttps://practicaldermatology.com/news/survey-despite-knowledge-parents-dont-drive-kids-sunscreen-use/2458142/According to a new Neutrogena Survey conducted online by Harris Poll, more than 4 in 5 parents of children under 18 years old say their children do not wear sunscreen on a daily basis— despite over 9 in 10 Americans believing sunscreen is important for protecting a child’s health.
- ASDS: Percentage of Us Wanting Cosmetic Surgery Doubled Since 2013https://practicaldermatology.com/news/asds-percentage-of-us-wanting-cosmetic-surgery-doubled-since-2013/2458141/Nearly 70 percent of consumers now say they are thinking about getting a cosmetic treatment, according to survey data released by the American Society for Dermatologic Surgery (ASDS). The ASDS Consumer
- Thumbs Down for Neothetics, Inc.'s LIPO-202; Stock Plummetshttps://practicaldermatology.com/news/thumbs-down-for-neothetics-incs-lipo-202/2458145/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares droppe
- Study Findings Cast Doubt on Link Between Eczema and Cardiovascular Diseasehttps://practicaldermatology.com/news/study-findings-cast-doubt-on-link-between-eczema-and-cardiovascular-disease/2458151/Despite recent findings to the contrary, a new study in the British Journal of Dermatology has found that eczema is likely not associated with an increase in cardiovascular risk factors or diseases. "In our study, people who reported having atopic dermatitis were not at any
- PsA Patients Failing Anti-TNF Drugs May Do Well on Taltzhttps://practicaldermatology.com/news/psa-patients-who-fail-anti-tnf-drugs-may-do-well-on-taltz/2458154/New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated. Eli Lilly has filed a supple